Astec Lifescienc

Why is Astec Lifesciences Ltd falling/rising?

As of 03-Aug, Astec Lifesciences Ltd's stock price is at 627.85, down 4.44%, with significant underperformance against the Sensex and a year-to-date decline of 10.97%. The company faces financial challenges, including operating losses and a high Debt to EBITDA ratio, contributing to negative market sentiment.

As of 03-Aug, Astec Lifesciences Ltd's stock price is falling, currently at 627.85, which reflects a decrease of 29.15 or 4.44%. The stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of 5.34% and a 1-month decline of 11.51%. Year-to-date, the stock is down 10.97%, and over the past year, it has fallen by 28.78%, indicating a consistent trend of underperformance.<BR><BR>Today's trading session saw the stock open with a loss of 3.3% and reach an intraday low of Rs 624.45, marking a decline of 4.95%. The performance today has been particularly poor, underperforming its sector by 6.43%. Additionally, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend.<BR><BR>The company's financial health is concerning, as it has reported operating losses and a high Debt to EBITDA ratio of -99.10 times, indicating a low ability to service debt. Furthermore, the company has recorded a negative EBIT of Rs. -38.71 crore and a low Return on Equity of 5.75%, signifying weak profitability. The net sales for the quarter have also decreased by 8.26%, contributing to the negative sentiment surrounding the stock.<BR><BR>Overall, the combination of poor financial results, significant losses, and consistent underperformance against benchmarks has led to the decline in Astec Lifesciences Ltd's stock price.

Which are the latest news on Astec Lifescienc?

Should I buy, sell or hold Astec Lifesciences Ltd?

When is the next results date for Astec Lifesciences Ltd?

Astec Lifesciences Ltd will announce its results on July 31, 2026.

Astec Lifesciences Ltd is scheduled to declare its results on July 31, 2026.

How big is Astec Lifescienc?

As of 10th June, Astec Lifesciences Ltd has a market capitalization of 1,745.00 Cr, with net sales of 448.14 Cr and a net loss of 80.93 Cr over the last four quarters. Shareholder's funds are valued at 234.75 Cr, and total assets amount to 881.42 Cr.

As of 10th June, <BR><BR>Market Cap: Astec Lifesciences Ltd has a market capitalization of 1,745.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 448.14 Cr, while the sum of Net Profit for the same period reflects a loss of 80.93 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 234.75 Cr, and Total Assets amount to 881.42 Cr.

Who are in the management team of Astec Lifescienc?

The management team of Astec Lifescience includes Ashok V Hiremath (Director), N B Godrej (Chairman), Balram Yadav (Director), Anurag Roy (Whole Time Director & CEO), and several independent directors, overseeing the company's operations and strategic direction.

The management team of Astec Lifescience includes the following individuals:<BR><BR>1. **Ashok V Hiremath** - Director<BR>2. **N B Godrej** - Chairman (Non-Executive)<BR>3. **Balram Yadav** - Director<BR>4. **Vijay Kashinath Khot** - Independent Director<BR>5. **Brahma Nand Vyas** - Independent Director<BR>6. **Tejashree Pradhan** - Company Secretary & Compliance Officer<BR>7. **Govindan Ramakrishna Rishinaradamangalam** - Independent Director<BR>8. **Dhekne Vasant Nandkumar** - Independent Director<BR>9. **Anjali Rajesh Gupta** - Independent Director<BR>10. **Anurag Roy** - Whole Time Director & CEO<BR>11. **Burjis Godrej** - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Astec Lifescienc?

Astec Lifescienc's peers include Bhagiradha Chemicals, Bharat Rasayan, Insecticides India, India Pesticides, Punjab Chemicals, Meghmani Organics, Dharmaj Crop, and Heranba Industries. Astec Lifescienc has below-average management risk and a 1-year return of -3.68%, better than Meghmani Organics but worse than Dharmaj Crop, which has the highest return at 0.44%.

Peers: The peers of Astec Lifescienc are Bhagiradha Chem., Bharat Rasayan, Insecticid.India, India Pesticides, Punjab Chemicals, Meghmani Organi., Dharmaj Crop, and Heranba Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bharat Rasayan, Insecticid.India, and India Pesticides, while Average management risk is found at Bhagiradha Chem., Punjab Chemicals, Dharmaj Crop, and Heranba Inds. Below Average management risk is noted for Astec Lifescienc and Meghmani Organi. Growth is rated as Good for Dharmaj Crop, Below Average for Bhagiradha Chem., Bharat Rasayan, Insecticid.India, India Pesticides, Punjab Chemicals, and Heranba Inds, and Below Average for Astec Lifescienc and Meghmani Organi. Capital Structure is Excellent for Bharat Rasayan, Insecticid.India, and India Pesticides, Good for Bhagiradha Chem. and Punjab Chemicals, Average for Meghmani Organi. and Heranba Inds, and Below Average for Astec Lifescienc.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dharmaj Crop at 0.44%, while the peer with the lowest is Meghmani Organi. at -48.86%. Astec Lifescienc's 1-year return is -3.68%, which is better than Meghmani Organi. but worse than Dharmaj Crop. Additionally, the six-month return is negative for Bharat Rasayan, Punjab Chemicals, Meghmani Organi., Heranba Inds, and India Pesticides.

What does Astec Lifescienc do?

Astec Lifesciences Ltd is a small-cap producer of agrochemicals and pharmaceutical intermediates, with recent net sales of 159 Cr and a net loss of 8 Cr as of March 2026. The company has a market cap of INR 1,745 Cr and key metrics indicating financial challenges, including a negative return on equity of -20.18%.

Overview:<BR>Astec Lifesciences Ltd is a producer of agrochemicals and pharmaceutical intermediates, operating within the small-cap segment of the Pesticides & Agrochemicals industry.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has maintained its status as a producer of agrochemicals and pharmaceutical intermediates. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 159 Cr (Quarterly Results - Mar 2026)<BR>- Most recent Net Profit: -8 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap value: INR 1,745 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 29<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 1.12<BR>- Return on Equity: -20.18%<BR>- Price to Book: 4.51<BR><BR>Contact Details:<BR>Address: GodrejOne 3rd Fl Pirojshanagar, Vikhroli (E) Eastern Exp Highw Mumbai Maharashtra : 400079<BR>Tel: 91-22-25188010<BR>Email: astecinfo@godrejastec.com<BR>Website: http://www.astecls.com

Are Astec Lifesciences Ltd latest results good or bad?

Astec Lifesciences Ltd's latest results show strong revenue growth of 27.18% quarter-on-quarter and 32.70% year-on-year, but the company reported a net loss of ₹7.76 crores, indicating ongoing profitability challenges. While there are positive signs, investors should be cautious due to the uncertain path to sustainable profitability.

Astec Lifesciences Ltd's latest results present a mixed picture. On one hand, the company reported a significant quarter-on-quarter revenue growth of 27.18%, reaching ₹158.62 crores, which is the highest quarterly revenue in recent periods. Year-on-year, revenue also increased by 32.70%. This indicates a positive trend in sales performance.<BR><BR>However, despite this revenue growth, the company continues to face challenges with profitability. In Q4 FY26, Astec reported a net loss of ₹7.76 crores, although this was an improvement of 50.57% compared to the previous quarter's loss of ₹15.70 crores. The operating margin, while improving to 5.77% from 3.20% in the previous quarter, remains significantly lower than historical levels, which were above 20%.<BR><BR>Overall, while there are signs of recovery in terms of revenue and operational performance, the ongoing losses and structural issues within the company, particularly in the context of a challenging agrochemical sector, suggest that the latest results are not entirely positive. Investors should remain cautious, as the path to sustainable profitability is still uncertain.

Is Astec Lifescienc technically bullish or bearish?

As of November 21, 2025, the technical trend for Astec Lifesciences is mildly bearish with mixed signals across various indicators, suggesting caution in the current market environment.

As of 21 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish with weak strength. Key indicators include a bearish MACD on the weekly timeframe, a mildly bullish MACD on the monthly, and a mildly bearish moving average on the daily. The RSI is bearish on the weekly and shows no signal on the monthly. While the Bollinger Bands indicate bullishness on the weekly, they are mildly bearish on the monthly. The KST remains bearish across both timeframes, and Dow Theory shows mildly bullish on the weekly but mildly bearish on the monthly. Overall, the mixed signals suggest caution in the current market environment for Astec Lifescienc.

How has been the historical performance of Astec Lifescienc?

Astec Lifescienc has experienced a significant decline in net sales and profitability, with losses increasing from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025, alongside a decrease in total assets and negative cash flow from operations.

Answer:<BR>The historical performance of Astec Lifescienc shows a declining trend in net sales and profitability over the past few years, culminating in significant losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Astec Lifescienc's net sales have decreased from 676.57 crore in March 2022 to 381.30 crore in March 2025, reflecting a downward trend in revenue generation. The total operating income followed a similar pattern, dropping from 676.57 crore in March 2022 to 381.30 crore in March 2025. The company's total expenditure, excluding depreciation, peaked at 551.91 crore in March 2023 but slightly decreased to 447.51 crore in March 2025. This resulted in an operating profit (PBDIT) that fell from 164.55 crore in March 2022 to a loss of 60.58 crore in March 2025. The profit before tax also turned negative, going from a profit of 121.13 crore in March 2022 to a loss of 140.99 crore in March 2025. Consequently, the profit after tax showed a similar decline, moving from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025. The company's total assets decreased from 979.41 crore in March 2023 to 881.42 crore in March 2025, while total liabilities also decreased from 974.93 crore to 881.42 crore during the same period. Cash flow from operating activities turned negative in March 2025, indicating challenges in generating cash from core operations. Overall, Astec Lifescienc has faced significant financial difficulties, leading to substantial losses and a decline in key financial metrics over the past few years.

Who are the top shareholders of the Astec Lifescienc?

The top shareholder of Astec Lifescienc is Godrej Agrovet Limited, with a 64.75% stake. Other shareholders include individual investors (19.62%), mutual funds (3.96%), and foreign institutional investors (0.25%), with Nippon Life India Trustee Ltd being the largest public shareholder at 2.35%.

The top shareholders of Astec Lifescienc include Godrej Agrovet Limited, which holds the largest stake at 64.75%. The company also has a diverse range of other shareholders, including individual investors who collectively own 19.62% of the shares. Additionally, mutual funds hold 3.96% across three schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.25% through eight different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund, holding 2.35%.

Has Astec Lifescienc declared dividend?

Astec Lifesciences Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of July 21, 2023. However, the dividend yield is 0%, and total returns over various periods show significant declines in stock price.

Astec Lifesciences Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 21 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -26.09%, the dividend return was 0%, resulting in a total return of -26.09%.<BR><BR>Over the past year, the price return was -30.47%, the dividend return was 0%, leading to a total return of -30.47%.<BR><BR>In the 2-year period, the price return was -43.16%, with a dividend return of 0.11%, culminating in a total return of -43.05%.<BR><BR>For the 3-year period, the price return was -55.72%, the dividend return was 0.17%, resulting in a total return of -55.55%.<BR><BR>In the 4-year period, the price return was -42.55%, with a dividend return of 0.33%, leading to a total return of -42.22%.<BR><BR>Over the last 5 years, the price return was 8.85%, the dividend return was 0.74%, resulting in a total return of 9.59%.<BR><BR>Overall, while Astec Lifesciences Ltd has declared a dividend, the total returns over various periods indicate significant declines in price, with only modest positive returns in the longer term. The dividend yield remains at 0%, suggesting limited income generation from dividends relative to the stock price.